ATOSSA THERAPEUTICS, INC. - Common Stock (ATOS) Institutional Ownership

13F Institutional Holders and Ownership History from Q2 2018 to Q4 2025

Type / Class
Equity / Common Stock
Symbol
ATOS on Nasdaq
Shares outstanding
129,337,627
Price per share
$0.59
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
19,380,482
Total reported value
$16,800,163
% of total 13F portfolios
0%
Share change
-1,959,628
Value change
-$1,649,339
Number of holders
63
Price from insider filings
$0.59
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of ATOSSA THERAPEUTICS, INC. - Common Stock (ATOS) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
VANGUARD GROUP INC 4.5% $4,841,495 5,833,127 The Vanguard Group 30 Jun 2025
CVI Investments, Inc. 4.3% $4,530,000 5,662,500 CVI Investments, Inc. 31 Dec 2024
BlackRock, Inc. 1.6% $1,717,392 2,094,891 BlackRock, Inc. 30 Jun 2025

As of 30 Sep 2025, 63 institutional investors reported holding 19,380,482 shares of ATOSSA THERAPEUTICS, INC. - Common Stock (ATOS). This represents 15% of the company’s total 129,337,627 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of ATOSSA THERAPEUTICS, INC. - Common Stock (ATOS) together control 15% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
VANGUARD GROUP INC 4.7% 6,078,844 +4.2% 0% $5,270,358
AMERIPRISE FINANCIAL INC 2.3% 2,951,505 -0.73% 0% $2,558,955
BlackRock, Inc. 1.5% 1,997,627 -7% 0% $1,731,943
MILLENNIUM MANAGEMENT LLC 1.3% 1,668,648 -19% 0% $1,446,718
RENAISSANCE TECHNOLOGIES LLC 1.2% 1,548,663 -15% 0% $1,342,691
GEODE CAPITAL MANAGEMENT, LLC 1.1% 1,362,282 +4.8% 0% $1,181,392
STATE STREET CORP 0.35% 454,495 -12% 0% $394,047
GSA CAPITAL PARTNERS LLP 0.24% 310,754 +509% 0.02% $269,000
NORTHERN TRUST CORP 0.2% 263,377 0% 0% $228,348
CITADEL ADVISORS LLC 0.2% 263,369 +203% 0% $228,341
UBS Group AG 0.2% 260,722 -37% 0% $226,046
Squarepoint Ops LLC 0.2% 253,343 +40% 0% $219,648
Connor, Clark & Lunn Investment Management Ltd. 0.19% 248,614 +25% 0% $215,548
SUSQUEHANNA INTERNATIONAL GROUP, LLP 0.17% 219,602 -20% 0% $190,395
Graham Capital Management, L.P. 0.13% 165,446 0.01% $143,442
JANE STREET GROUP, LLC 0.13% 162,428 -65% 0% $140,825
BANK OF AMERICA CORP /DE/ 0.12% 155,169 +56% 0% $134,532
Qube Research & Technologies Ltd 0.11% 138,643 -67% 0% $120,203
MORGAN STANLEY 0.09% 112,348 -30% 0% $97,406
ACADIAN ASSET MANAGEMENT LLC 0.08% 97,287 0% $82,000
MARSHALL WACE, LLP 0.07% 85,076 +535% 0% $74,015
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.06% 80,000 0% 0% $69,360
COMMONWEALTH EQUITY SERVICES, LLC 0.04% 46,001 0% 0% $40,000
Point72 Asia (Singapore) Pte. Ltd. 0.03% 44,106 -50% 0.01% $38,240
JPMORGAN CHASE & CO 0.03% 38,215 +1294% 0% $33,132

Institutional Holders of ATOSSA THERAPEUTICS, INC. - Common Stock (ATOS) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 61,037 $35,622 +$92 $0.59 5
2025 Q3 19,380,482 $16,800,163 -$1,649,339 $0.87 63
2025 Q2 21,349,209 $17,720,003 -$5,653,305 $0.83 82
2025 Q1 28,359,111 $19,084,789 -$1,341,003 $0.67 82
2024 Q4 29,931,066 $28,256,526 +$2,338,368 $0.94 83
2024 Q3 27,342,806 $41,556,220 +$1,106,466 $1.52 85
2024 Q2 26,185,969 $31,162,750 +$6,136,738 $1.19 74
2024 Q1 19,247,212 $34,645,211 +$6,651,468 $1.80 64
2023 Q4 15,977,339 $14,108,531 -$98,734 $0.88 47
2023 Q3 16,179,139 $11,915,565 -$5,714 $0.74 50
2023 Q2 16,001,766 $20,161,211 -$384,693 $1.26 48
2023 Q1 16,381,798 $11,876,091 -$1,061,782 $0.72 41
2022 Q4 17,942,376 $9,491,902 -$744,052 $0.53 48
2022 Q3 19,012,323 $15,840,090 -$3,865,790 $0.83 44
2022 Q2 23,270,576 $25,392,308 -$11,443,285 $1.09 61
2022 Q1 33,773,484 $42,226,500 -$5,308,588 $1.25 71
2021 Q4 39,320,369 $63,309,166 +$10,803,111 $1.60 82
2021 Q3 30,993,684 $101,545,957 -$24,704,471 $3.26 86
2021 Q2 35,452,360 $224,051,807 +$172,782,844 $6.32 80
2021 Q1 10,827,609 $22,844,136 +$19,269,267 $2.11 50
2020 Q4 1,579,871 $1,500,720 +$453,590 $0.95 12
2020 Q3 738,286 $1,785,592 +$1,033,409 $2.42 21
2020 Q2 311,346 $1,182,680 +$252,483 $3.79 9
2020 Q1 239,786 $319,620 -$72,670 $1.33 7
2019 Q4 300,532 $471,410 +$55,888 $1.57 11
2019 Q3 261,639 $513,480 +$3,000 $1.96 10
2019 Q2 253,600 $647,150 -$201,112 $2.55 8
2019 Q1 307,555 $764,360 -$504,032 $3.50 9
2018 Q4 781,895 $798,000 +$220,145 $1.02 13
2018 Q3 566,336 $990,000 -$8,444 $1.74 7
2018 Q2 534,782 $1,176,000 +$1,176,000 $2.19 9